IGF-1 LR3 is a long-acting analog of Insulin-like Growth Factor 1, modified to reduce IGFBP binding and extend active half-life to approximately 20–30 hours. Lyophilized powder. For research use only.
$60.00
IGF-1 LR3 is a recombinant IGF-1 analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF binding proteins, extending active half-life to approximately 20–30 hours versus the ~15 minutes of native IGF-1.
The compound binds the IGF-1 receptor with full affinity, activating PI3K/Akt and MAPK/ERK signaling pathways studied in the context of cellular proliferation, glucose uptake, and protein synthesis.
IGF-1 LR3 is a recombinant IGF-1 analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF binding proteins, extending active half-life to approximately 20–30 hours versus the ~15 minutes of native IGF-1.
The compound binds the IGF-1 receptor with full affinity, activating PI3K/Akt and MAPK/ERK signaling pathways studied in the context of cellular proliferation, glucose uptake, and protein synthesis.
All products are sold for research, laboratory, or analytical purposes only, and are not for human consumption. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease. Synthic Research is a chemical supplier. Synthic Research is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act. Synthic Research is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic act.
